Immunology / Virology & Vaccines

Doctor prepares vaccine
#Covid-19 #Immunodeficiency #Immunology / Virology & Vaccines

New study on vaccine responses for impaired immune systems

A new UK study by Octave seeks to understand the immune response to COVID-19 vaccinations in patients with certain immunosuppressed conditions, including cancer. Funded by the Medical Research Council (MRC), researchers from the Universities of Glasgow, Birmingham (sponsors), Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust will… Read More

#Covid-19 #News

#Assay development optimisation & technology #Covid-19 #Immunology / Virology & Vaccines

Bio-Rad launches new SARS-CoV-2 serology assay panel

Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox,… Read More

#Covid-19 #News

#Coronavirus #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Pandemic #Sitting Down With #Therapeutics

How critical is the part therapeutics have to play in the pandemic?

This DDW Sponsored Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode  – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the… Read More

#Podcasts

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine pill a possibility?

Professor Sarah Gilbert, head of the team behind the Oxford AstraZeneca COVID-19 vaccine, has told UK MPs that there is a possibility the vaccine could be taken orally and perhaps also via a nasal spray. Reported in The Guardian newspaper today, she was asked by MP Graham Stringer how the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Pfizer and AstraZeneca COVID-19 vaccine working, suggests Scottish study

The study is the first to describe across an entire country the effect of the Pfizer and Oxford-AstraZeneca jabs in the community on preventing severe illness resulting in hospitalisation. Previous results about vaccine efficacy have come from clinical trials. Hospitalisation drop By the fourth week after receiving the initial dose,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK start new Phase II study of their COVID-19 vaccine candidate

Sanofi and GlaxoSmithKline (GSK) have begun a new Phase II study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase III evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. “Over the past few weeks, our teams have worked to refine the antigen… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Human trials #Immunology / Virology & Vaccines

World’s first coronavirus Human Challenge study receives ethics approval

The UK will be the first country in the world to run a COVID-19 human challenge study, following approval from the UK’s clinical trials ethics body. Backed by a £33.6 million UK government investment, the first-of-its-kind study for this virus will involve establishing the smallest amount of virus needed to… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

World Health Organization experts provide guidance on use of the Oxford vaccine

The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) has produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. The WHO has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at an 8-… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Recruitment begins for Phase III trial of Janssen’s COVID-19 vaccine candidate

The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate. The Phase III ENSEMBLE 2 study is… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine data on protection against COVID-19 infection from South African variant

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa. Efficacy against severe COVID-19 infection from this variant was not assessed. The analyses being… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Oxford AstraZeneca vaccine effective against ‘Kent’ variant

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants. The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it… Read More

#Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Novavax announces rolling review for COVID-19 vaccine authorisation

Novavax has announced the start of the rolling review process for authorisation of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its Phase III trials in the UK and US and through initial authorisation for emergency use granted under country-specific regulations. “The… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Research

Oxford University leads first trial into dosing with alternating vaccines

The University of Oxford has reported  it is to lead the first trial looking into alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains. The study, run by the National… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

GSK and CureVac collaboration to develop COVID-19 vaccine for multi-variants

GlaxoSmithKline and CureVac have signed a €150m (£132m) deal to jointly develop next generation mRNA vaccines for COVID-19. They aim to work together to develop a single vaccine that can address the multiple emerging variants. GSK will also support the manufacture of up to 100 million doses of CureVac’s first… Read More

#Covid-19 #Editor's Choice #News #Trending News